Israel21C via JNS
By Jon Schiller
A new study sheds light on how our brain decides when we should start and stop eating, offering hope for anti-obesity drugs.
When Hebrew University of Jerusalem medical student Hadar Israeli studied a family with multiple members suffering from severe obesity and plagued with constant hunger, she found that they all shared a common mutation affecting a specific receptor in the brain: Melanocortin Receptor 4, or MC4.
Though scientists have long known that the MC4 receptor was in some way connected to hunger and appetite, Israeli helped uncover just how instrumental it was in regulating our sensations of hunger and fullness.
To further investigate this matter, Israeli turned to Moran Shalev-Benami of the Weizmann Institute’s chemical and structural biology department. Could new advances in electron microscopy help explain how this mutation produces such a devastating effect of constant hunger?
Shalev-Benami decided to launch a study into the structure of MC4, inviting Israeli to join her lab as a visiting scientist.
Together with postdoctoral fellow Oksana Degtjarik, Israeli isolated large quantities of pure MC4 receptors from cell membranes and let them bind with a drug used to treat obesity called Setmelanotide. They then determined MC4’s structure using cryogenic electron microscopy.
The 3D modeling revealed that Setmelanotide activates the MC4 receptor by entering its binding pocket—that is, by directly hitting the molecular switch that signals fullness, even more potently than the natural satiety hormone.
Furthermore, they discovered that when entering the MC4 receptor’s binding pocket, an ion of calcium enters as well, enhancing the drug’s ability to bind to the receptor.
“This was a truly unexpected finding,” said Shalev-Benami. “Apparently, the satiety signal can successfully compete with the hunger signal because it benefits from the assistance of calcium, which helps the brain restore the ‘I’m full’ sensation after we eat.”
The findings may help develop improved and safer anti-obesity drugs that will target the MC4 receptor with greater precision.
The study, published in Science on April 15, included additional researchers from Hebrew University, Weizmann Institute of Science and Queen Mary University of London.
This article was originally published by Israel21c.
Caption: An overweight person weighs in.
Credit: Wikimedia Commons.
